Heart failure & cardiomyopathies
Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program
Authors' conclusion
The replication of mechanistic signatures across discovery and validation cohorts closely aligns with the experimental effects of SGLT2 inhibitors.
Study context
- Population
- Patients with HF with reduced or preserved EF in the EMPEROR programdiscovery 1,134
- Comparison
- Empagliflozin vs placebo
Methodological detailsdouble-blind, randomised, discovery and validation cohorts
- Double-blind
- Randomised
- Discovery and validation cohorts
Main finding
As reported in the abstract
Proteins differentially enriched by empagliflozin (validation cohort) · 12 weeks
- Most differentially enriched proteins (≥15% between-group difference, false discovery rate <1%, known heart or kidney effects)
- 25
- Proteins promoting autophagy and cellular quality control
- 13
- Proteins enhancing mitochondrial health and ATP production
- 12
- Proteins augmenting iron mobilization or erythropoiesis
- 7
- Proteins influencing renal tubular sodium handling
- 3
- Proteins with restorative effects in heart or kidneys
- 9
Further findings
Differentially enriched proteins at ≥10% threshold
- Additional differentially enriched proteins with heart and kidney actions; biological signatures unchanged
- 58
Original publication
Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program. J Am Coll Cardiol. Published 31 August 2024. doi:10.
Summarised from the published abstract; every number is checked against it